These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 32891131)

  • 21. Comparison of efficacy and safety of preoperative Chemoradiotherapy in locally advanced upper and middle/lower rectal cancer.
    Huang MY; Lee HH; Tsai HL; Huang CW; Yeh YS; Ma CJ; Huang CM; Chen CY; Huang JJ; Wang JY
    Radiat Oncol; 2018 Mar; 13(1):53. PubMed ID: 29587797
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relations of Changes in Serum Carcinoembryonic Antigen Levels before and after Neoadjuvant Chemoradiotherapy and after Surgery to Histologic Response and Outcomes in Patients with Locally Advanced Rectal Cancer.
    Saito G; Sadahiro S; Ogimi T; Miyakita H; Okada K; Tanaka A; Suzuki T
    Oncology; 2018; 94(3):167-175. PubMed ID: 29268274
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Efficacy analysis of neoadjuvant chemoradiotherapy combined with total pelvic exenteration in the treatment of primary T4b rectal cancer].
    Wu T; Wen L; Zhang J; Wu Y; Jiang Y; Chen G; Wang X; Huang S; Wan Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):59-65. PubMed ID: 30703795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beneficiaries of radical surgery among clinical complete responders to neoadjuvant chemoradiotherapy in rectal cancer.
    Zhang S; Zhang R; Li RZ; Wang QX; Chang H; Ding PR; Li LR; Wu XJ; Chen G; Zeng ZF; Xiao WW; Gao YH
    Cancer Sci; 2021 Sep; 112(9):3607-3615. PubMed ID: 34146368
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MRI features and texture analysis for the early prediction of therapeutic response to neoadjuvant chemoradiotherapy and tumor recurrence of locally advanced rectal cancer.
    Park H; Kim KA; Jung JH; Rhie J; Choi SY
    Eur Radiol; 2020 Aug; 30(8):4201-4211. PubMed ID: 32270317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tolerability, Safety, and Outcomes of Neoadjuvant Chemoradiotherapy With Capecitabine for Patients Aged ≥ 70 Years With Locally Advanced Rectal Cancer.
    Jacobs L; van der Vlies E; Ten Bokkel Huinink D; Bloemendal H; Intven M; Smits AB; Weusten BLAM; Siersema PD; van Lelyveld N; Los M
    Clin Colorectal Cancer; 2018 Sep; 17(3):179-186. PubMed ID: 29661620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lymph Node Regression to Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer: Prognostic Implication and a Predictive Model.
    Sun Y; Wu X; Lin H; Lu X; Huang Y; Chi P
    J Gastrointest Surg; 2021 Apr; 25(4):1019-1028. PubMed ID: 32219686
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A nomogram for predicting good response after neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a retrospective, double-center, cohort study.
    Wang G; Zheng Z; Chen J; Ye J; Tang Z; Fang Y; Yao K; Zeng Q; Yang Y; Tang H; Lin B; Guo Y; Huang Y
    Int J Colorectal Dis; 2022 Oct; 37(10):2157-2166. PubMed ID: 36048198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes in serum uric acid, serum uric acid/serum creatinine ratio, and gamma-glutamyltransferase might predict the efficacy of neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer.
    Shao Z; Xu Y; Zhang X; Zou C; Xie R
    Strahlenther Onkol; 2024 Jun; 200(6):523-534. PubMed ID: 37286741
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of tumor response after neoadjuvant chemoradiotherapy in rectal cancer using (18)fluorine-2-deoxy-D-glucose positron emission tomography-computed tomography and serum carcinoembryonic antigen: a prospective study.
    Li QW; Zheng RL; Ling YH; Wang QX; Xiao WW; Zeng ZF; Fan W; Li LR; Gao YH
    Abdom Radiol (NY); 2016 Aug; 41(8):1448-55. PubMed ID: 27116012
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MRI T2-weighted sequences-based texture analysis (TA) as a predictor of response to neoadjuvant chemo-radiotherapy (nCRT) in patients with locally advanced rectal cancer (LARC).
    Crimì F; Capelli G; Spolverato G; Bao QR; Florio A; Milite Rossi S; Cecchin D; Albertoni L; Campi C; Pucciarelli S; Stramare R
    Radiol Med; 2020 Dec; 125(12):1216-1224. PubMed ID: 32410063
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A dynamic nomogram for predicting pathologic complete response to neoadjuvant chemotherapy in locally advanced rectal cancer.
    Wang G; Li J; Huang Y; Guo Y
    Cancer Med; 2024 Jun; 13(11):e7251. PubMed ID: 38819440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of pathological response and lymph node metastasis after neoadjuvant therapy in rectal cancer through tumor and mesorectal MRI radiomic features.
    Qin S; Liu K; Chen Y; Zhou Y; Zhao W; Yan R; Xin P; Zhu Y; Wang H; Lang N
    Sci Rep; 2024 Sep; 14(1):21927. PubMed ID: 39304726
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mucinous histology is a negative predictor of neoadjuvant chemoradiotherapy for locally advanced rectal adenocarcinoma.
    Tan X; Zhang Y; Wu X; Fang Q; Xu Y; Li S; Yuan J; Peng X; Fu K; Xiao S
    BMC Gastroenterol; 2024 Aug; 24(1):263. PubMed ID: 39138423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enrichment of CD133-expressing cells in rectal cancers treated with preoperative radiochemotherapy is an independent marker for metastasis and survival.
    Sprenger T; Conradi LC; Beissbarth T; Ermert H; Homayounfar K; Middel P; Rüschoff J; Wolff HA; Schüler P; Ghadimi BM; Rödel C; Becker H; Rödel F; Liersch T
    Cancer; 2013 Jan; 119(1):26-35. PubMed ID: 22736392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FOSL2 promotes intertumoral infiltration of T cells and increases pathological complete response rates in locally advanced rectal cancer patients.
    Xu K; Yin X; Zhou B; Zheng X; Wang H; Chen J; Cai X; Gao H; Xu X; Wang L; Shen L; Guo T; Zheng S; Li B; Shao Y; Wang J
    Cancer Lett; 2023 May; 562():216145. PubMed ID: 36997107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting the pathological response to neoadjuvant chemoradiation using untargeted metabolomics in locally advanced rectal cancer.
    Jia H; Shen X; Guan Y; Xu M; Tu J; Mo M; Xie L; Yuan J; Zhang Z; Cai S; Zhu J; Zhu Z
    Radiother Oncol; 2018 Sep; 128(3):548-556. PubMed ID: 30041962
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical outcomes of elderly patients receiving neoadjuvant chemoradiation for locally advanced rectal cancer.
    Jiang DM; Raissouni S; Mercer J; Kumar A; Goodwin R; Heng DY; Tang PA; Doll C; MacLean A; Powell E; Price-Hiller J; Monzon J; Cheung WY; Vickers MM
    Ann Oncol; 2015 Oct; 26(10):2102-6. PubMed ID: 26232491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of mesorectal package area in patients with locally advanced rectal cancer following neoadjuvant chemoradiotherapy: A retrospective cohort study.
    Guan B; Huang X; Xia H; Guan G; Xu B
    Front Oncol; 2022; 12():941786. PubMed ID: 36263216
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does Delaying Surgical Resection After Neoadjuvant Chemoradiation Impact Clinical Outcomes in Locally Advanced Rectal Adenocarcinoma?: A Single-Institution Experience.
    Nguyen P; Wuthrick E; Chablani P; Robinson A; Simmons L; Wu C; Arnold M; Harzman AE; Husain S; Schmidt C; Abdel-Misih S; Bekaii-Saab T; Chakravarti A; Williams TM
    Am J Clin Oncol; 2018 Feb; 41(2):140-146. PubMed ID: 26535992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.